Pediatric psoriasis: Biologics and oral small molecule inhibitors in modern therapy

Therapeutic options are expanding for pediatric patients with psoriasis. Here, we offer an overview of the current treatment landscape for pediatric psoriasis, focusing on the increasing role of biologics and oral small molecules. Each therapeutic is discussed in terms of dosage, safety profile, and assessment through measures such as the Psoriasis Area Severity Index and the Children's Dermatology Life Quality Index, where data are available. We highlight the important pediatric-specific clinical trials as well as infer potential for pediatric therapy based on available adult trials. There has been a steady increase in pediatric psoriasis trials, but there is a continued need for more pediatric-focused research. Additional trials and therapeutics that match adult trials would substantially refine therapeutic decision-making and improve outcomes in this demographic.